Interpace Diagnostics Group ( (IDXG) ) has issued an update.
At the August 20, 2026 annual meeting, Interpace Biosciences’ stockholders approved giving the board discretion to implement a reverse stock split between 1-for-2 and 1-for-10, and the board subsequently set the ratio at 1-for-5. Following the filing of an amendment to its certificate of incorporation in Delaware on August 25, 2026, the 1-for-5 reverse split became effective at 12:01 a.m. Eastern Time on August 27, 2026, reducing the number of outstanding shares from about 27.7 million to roughly 5.5 million.
The company’s common stock began trading on a split-adjusted basis on the OTCID quotation system on August 27, 2026, with a temporary ticker change to IDXGD and a new CUSIP assigned, while fractional shares were rounded up and most shareholders needed to take no action. The reverse split triggers proportional adjustments to equity awards and plan share reserves and is a key element of Interpace’s strategy to pursue an uplisting to the Nasdaq Capital Market, aimed at meeting minimum bid price requirements, supporting growth plans and potentially broadening its investor base, though the company noted it must still satisfy additional Nasdaq listing criteria.
Spark’s Take on IDXG Stock
According to Spark, TipRanks’ AI Analyst, IDXG is a Neutral.
The score is primarily supported by improved financial health (profitability turnaround, low leverage, and positive cash flow). Offsetting this are declining revenue and weakening cash conversion in TTM, while technicals are largely neutral. Valuation appears very low based on P/E, but the potential reverse-split authorization adds a modest risk factor.
To see Spark’s full report on IDXG stock,
click here.
More about Interpace Diagnostics Group
Interpace Biosciences, Inc. is an emerging personalized medicine company focused on molecular diagnostics and related clinical services. Through its Interpace Diagnostics unit, the company offers bioinformatics and pathology services to assess cancer risk, anchored by commercial tests ThyGeNEXT® and ThyraMIR®v2 for thyroid cancer diagnosis using next-generation sequencing and proprietary microRNA profiling.
The company’s offerings span the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Interpace targets clinicians and healthcare providers seeking advanced diagnostic tools to improve patient management, positioning itself within the growing market for precision oncology and specialized molecular testing.
Average Trading Volume: 5,403
Technical Sentiment Signal: Sell
Current Market Cap: $39.34M
See more insights into IDXG stock on TipRanks’ Stock Analysis page.
Trending Articles:
This story was written using TipRanks's AI tools and reviewed by a TipRanks editor.